| Autor: |
Zhang W; Centre for Health Evaluation and Outcome Sciences, Providence Research, St. Paul's Hospital, 570-1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada.; School of Population and Public Health, University of British Columbia, 2206 East Mall, Vancouver, BC V6T 1Z3, Canada., Guh DP; Centre for Health Evaluation and Outcome Sciences, Providence Research, St. Paul's Hospital, 570-1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada., Mohammadi T; Centre for Health Evaluation and Outcome Sciences, Providence Research, St. Paul's Hospital, 570-1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada., Pataky RE; Canadian Centre for Applied Research in Cancer Control, BC Cancer, 675 West 10th Avenue, Vancouver, BC V5Z 1L3, Canada., Tam ACT; Centre for Health Evaluation and Outcome Sciences, Providence Research, St. Paul's Hospital, 570-1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada.; School of Population and Public Health, University of British Columbia, 2206 East Mall, Vancouver, BC V6T 1Z3, Canada., Lynd LD; Centre for Health Evaluation and Outcome Sciences, Providence Research, St. Paul's Hospital, 570-1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada.; Faculty of Pharmaceutical Sciences, University of British Columbia, 2405 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada., Conklin AI; Centre for Health Evaluation and Outcome Sciences, Providence Research, St. Paul's Hospital, 570-1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada.; Faculty of Pharmaceutical Sciences, University of British Columbia, 2405 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada. |
| Abstrakt: |
We aimed to estimate the total health care costs attributable to prostate cancer (PCa) during care phases by age, cancer stage, tumor grade, and primary treatment in the first year in British Columbia (BC), Canada. Using linked administrative health data, we followed a cohort of men aged ≥ 50 years at diagnosis with PCa between 2010 and 2017 (Cohort 1) from the diagnosis date until the date of death, the last date of observation, or 31 December 2019. Patients who died from PCa after 1 January 2010, were selected for Cohort 2. PCa attributable costs were estimated by comparing costs in patients to matched controls. Cohort 1 ( n = 22,672) had a mean age of 69.9 years (SD = 8.9) and a median follow-up time of 5.2 years. Cohort 2 included 6942 patients. Mean PCa attributable costs were the highest during the first year after diagnosis ($14,307.9 [95% CI: $13,970.0, $14,645.8]) and the year before death ($9959.7 [$8738.8, $11,181.0]). Primary treatment with radiation therapy had significantly higher costs each year after diagnosis than a radical prostatectomy or other surgeries in advanced-stage PCa. Androgen deprivation therapy (and/or chemotherapy) had the highest cost for high-grade and early-stage cancer during the three years after diagnosis. No treatment group had the lowest cost. Updated cost estimates could inform economic evaluations and decision-making. |
